T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: A plain language summary of the DESTINY-Breast04 study
Modi S
Future Oncol. 2025:1-14. doi: 10.1080/14796694.2024.2434388.
Edoxaban
Cardiovascular - AF
Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry
Wang C-C, Cheng C-I, Ueng K-C, et al.
J Arrhythm. 2025;41(1):e13212. doi: 10.1002/joa3.13212.
HER3-DXd, T-DXd
Breast Cancer
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: Potential for biomarker-driven sequencing of T-DXd and HER3-DXd
Singer CF, Jahn SW, Hlauschek D, et al.
Cancer Commun (Lond). 2025. doi: 10.1002/cac2.12657.
Dato-DXd
Lung Cancer
Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study
Sands J, Ahn M-J, Lisberg A, et al.
J Clin Oncol. 2025 Apr;43(10):1254-1265. doi: 10.1200/JCO-24-01349.
T-DXd
Gastric Cancer
The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer
Koganemaru S, Koyama S, Suto F, et al.
Cancer Res Commun. 2025;5(1):84-93. doi: 10.1158/2767-9764.CRC-24-0302.
Pexidartinib
Other/Multi
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Desai J, Wagner AJ, Carrasco Garcia I, et al.
Cancer. 2025;131(1):e35634. doi: 10.1002/cncr.35634.
T-DXd
Breast Cancer
Cost-effectiveness of trastuzumab deruxtecan in patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy
Paulissen JHJ, van Schoonhoven AV, Olin E, et al.
Adv Ther. 2025;42(1):322-333. doi: 10.1007/s12325-024-03033-2
Edoxaban
Cardiovascular - AF
Impact of diagnostic coding schemas on major bleeding risk assessment for oral anticoagulants in patients with atrial fibrillation using administrative claims data
Chien H-T, Chao T-F, Wang R, et al.
J Thromb Haemost. 2024:S1538-7836(24)00730-X. doi: 10.1016/j.jtha.2024.12.010.
Other/Multi
Lung Cancer
A podcast discussion on the intracranial efficacy of antibody-drug conjugates in patients with EGFR-mutated NSCLC with brain metastases
Johnson ML, Lin JJ, Boire A, Khandekar MJ, Yu HA
Oncol Ther. 2024. doi: 10.1007/s40487-024-00315-1.
T-DXd
Breast Cancer Other/Multi
Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: Analysis of the phase 1b DS8201-A-U105 study
Hamilton E, Galsky MD, Ochsenreither S, et al.
Clin Cancer Res. 2024. doi: 10.1158/1078-0432.CCR-24-1513. Epub ahead of print.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26